Payment overview · 2025
General Payments
$459.25
22 reported records · 11 companies
Healthcare provider profile · identity verified
Randy W Head, MD APMC
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, LA · NPI 1417930843
Verified facts
What the public records show
CMS Open Payments records show Randy W Head, MD APMC received $459.25 in general payments during 2025 across 22 reported records.
Inspire Medical Systems, Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $98.00 | 21.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.74 | 16.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.40 | 10.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.01 | 9.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.80 | 9.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.55 | 8.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.27 | 7.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.41 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.92 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.82 | 3.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.33 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.25 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $98.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.80 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 388 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
388 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 403 | 84 |
| Eliquis | Apixaban | 388 | 54 |
| Potassium Chloride | Potassium Chloride | 358 | 72 |
| Furosemide | Furosemide | 348 | 75 |
| Gabapentin | Gabapentin | 348 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 75 |
| Metformin Hcl | Metformin Hcl | 284 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 228 | 48 |
| Alprazolam | Alprazolam | 217 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 202 | 47 |
| Lisinopril | Lisinopril | 202 | 40 |
| Omeprazole | Omeprazole | 201 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 176 | 56 |
| Valsartan | Valsartan | 174 | 51 |
| Carvedilol | Carvedilol | 149 | 31 |
| Meloxicam | Meloxicam | 148 | 31 |
| Azithromycin | Azithromycin | 140 | 110 |
| Montelukast Sodium | Montelukast Sodium | 137 | 29 |
| Trazodone Hcl | Trazodone Hcl | 134 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 26 |
| Donepezil Hcl | Donepezil Hcl | 119 | 24 |
| Clonazepam | Clonazepam | 113 | 27 |
| Memantine Hcl | Memantine Hcl | 113 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 19 |
| Nifedipine Er | Nifedipine | 98 | 25 |
| Ondansetron Odt | Ondansetron | 98 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 25 |
| Losartan Potassium | Losartan Potassium | 89 | 26 |
| Finasteride | Finasteride | 87 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 24 |
| Fluconazole | Fluconazole | 80 | 47 |
| Tramadol Hcl | Tramadol Hcl | 79 | 14 |
| Ozempic | Semaglutide | 78 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 13 |
| Sertraline Hcl | Sertraline Hcl | 76 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | suppressed |
| Ezetimibe | Ezetimibe | 62 | 14 |
| Clonidine Hcl | Clonidine Hcl | 61 | 16 |
| Levetiracetam | Levetiracetam | 61 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 36 |
| Allopurinol | Allopurinol | 58 | 14 |
| Sucralfate | Sucralfate | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 56 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 45 |
| Rexulti | Brexpiprazole | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 47 |
| Dexamethasone | Dexamethasone | 50 | 32 |
| Mirtazapine | Mirtazapine | 49 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Prednisone | Prednisone | 46 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 13 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Nystatin | Nystatin | 35 | 19 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Rivastigmine | Rivastigmine | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 13 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 14 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Misoprostol | Misoprostol | 26 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 12 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Famotidine | Famotidine | 22 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 19 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Admelog | Insulin Lispro | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Topiramate | Topiramate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.25 · 22 records | Inspire Medical Systems, Inc. | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, IBSRELA, INSPIRE, JARDIANCE, MOUNJARO, NURTEC ODT, PREVNAR 20, QULIPTA, REXULTI, UBRELVY, VRAYLAR, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error